Phase 1 trials are necessary to evaluate the safety and toxicity of novel multimodality treatment (MMT) prior to routine clinical use. In the era of targeted therapies, phase 1 trials are increasingly used to justify clinical application in selected patient populations, without prospective assessment of outcomes.
1 Despite several published guidelines 2,3 regarding the reporting of phase 1 trials, details regarding therapeutic intent, median follow-up time, and late toxic effects remain poorly documented. In particular, late radiation-related complications are often underreported, despite late toxic effects significantly impacting patient morbidity and mortality. 4 We performed a systematic review of phase 1 trials involving radiation plus systemic therapeutics (novel agent or chemotherapy) to evaluate the frequency with which clinical efficacy is prospectively identified as an end point, median follow-up time reported, and late toxic effects delineated in published articles.
Methods | We systematically identified modern phase 1 MMT trials in the PubMed database with selection and exclusion criteria as delineated in the Figure. Each trial was evaluated for details regarding clinical efficacy as a prespecified end point (ie, prospective therapeutic intent), reporting of clinical outcomes (with or without prespecified end points), median follow-up time, reported grade 3 or higher and dose-limiting toxic effects, and distinction of acute and late radiation toxic effects. Associations of study characteristics with these end points were evaluated using exact χ 2 tests (P < .05) and pairwise exact χ 2 test comparisons; associations with follow-up time were evaluated using Kruskal-Wallis and pairwise comparisons using Dunn procedure 5 using SAS statistical software (version 9.4;
SAS Institute).
Results | The PubMed query methodology and results are outlined in the Figure. The percentage of trials that reported prospectively identified clinical end points, clinical outcomes, median follow-up time, and late toxic effects are delineated in the tribute late toxic effects to specific drug radiation combinations is complicated by early patient mortality and confounding treatments. However, because investigators are obligated to their patients and peers to evaluate toxic effects from investigational treatments, we propose that (3) assessment and reporting of late toxic effects be included in phase 1 trials. Limitations of this study include the time period evaluated, that it is a single database query, and that it only includes published trials and toxic effects. ClinicalTrials.gov was not included because trial registration is not mandated as a condition of publication for phase 1 trials. 6 However, these data identify 3 important measures, which if addressed, will improve the quality, availability, and interpretability of phase 1 trials.
